Jan 13 2010
NexMed, Inc. (Nasdaq: NEXM),
a specialty CRO and a developer of products based on the NexACT®
technology, today announced that pre-clinical results from its research
and development group at Bio-Quant successfully demonstrated the ability
of the NexACT technology to deliver an oral formulation of Taxol®
(paclitaxel) and to enhance the drug’s bioavailability by approximately
ten-fold through this oral administration. Taxol, a first line
chemotherapy drug used to treat breast, lung and ovarian cancers, is
currently administered through an intravenous infusion that can take up
to 24 hours to complete.
Dr. Bassam Damaj, NexMed’s Chief Executive Officer stated, “The results
from these proof of concept studies are exciting and support our belief
that NexACT can be successfully used to enhance oral bioavailability of
a broad range of drugs, which could include our proprietary drug
candidates, generic drugs and proprietary drugs owned by others who are
developing second-generation formulations to provide extended patent
protection with increased convenience and bioavailability. Our ability
to leverage our proprietary NexACT technology in this way is expected to
provide exciting new development opportunities and will no longer
restrict us to the topical delivery of dermal drugs. Additional studies
are ongoing to extend the validation of the technology into other
classes of oral drugs.”
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy